Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Braz. j. pharm. sci ; 51(3): 629-635, July-Sept. 2015. tab, graf
Article in English | LILACS | ID: lil-766314

ABSTRACT

Norfloxacin is one of the first commercially available (and most widely used) fluoroquinolone antibiotics. This paper reports the development and validation of a simple, sensitive, accurate and reproducible turbidimetric assay method to quantify norfloxacin in tablets formulations in only 4 hours. The bioassay is based on the inhibitory effect of norfloxacin upon the strain ofStaphylococcus epidermidis ATCC 12228 IAL 2150 used as test microorganism. The assay was performed 3x3 parallel lines like, three tubes for each concentration of reference substance and three tubes for each sample concentration. The results were treated statistically by analysis of variance and were found to be linear (r2 = 0.9999) in the selected range of 25-100 μg mL-1; precise (intra-assay: relative standard deviation (RSD) = 1.33%; inter-assay: RSD = 0.21%), accurate (100.74%) and robust with RSD lower than 4.5%. The student's t-test showed no statistically significant difference between the proposed turbidimetric method and an HPLC method previously validated. However the turbidimetric assay can be used as a valuable alternative methodology for the routine quality control of this medicine, complementary to other physical-chemical methods.


O norfloxacino foi a primeira fluorquinolona (e mais utilizada) disponível no mercado. Este trabalho divulga um novo desenvolvimento e validação de um método turbidimétrico simples, sensível, preciso e reprodutível para a quantificação de norfloxacino em comprimidos em apenas 4 horas. O bioensaio é baseado no efeito inibitório de norfloxacino sobre a cepa Staphylococcus epidermidis ATCC 12228 IAL 2150, utilizada como micro-organismo teste. O bioensaio foi efetuado através do delineamento de linhas paralelas 3x3, em que três tubos foram utilizados para a solução padrão e três tubos para as concentrações da amostra. Os resultados foram tratados estatisticamente pela análise de variância, apresentando coeficiente de correlação linear der2 = 0,9999, na faixa de 20 a 100 μg mL-1; precisão (intra-ensaio: desvio padrão relativo (RSD) 1,33%; inter-ensaio: RSD=0,21%), exatidão (100,74%) e robustez com RSD menor que 4,5%. O teste-tmostrou não haver diferença estatisticamente significativa entre o método turbidimétrico proposto e um método por HPLC previamente validado. No entanto, o ensaio turbidimétrico pode ser utilizado como método alternativo para o controle de qualidade de rotina para este antimicrobiano, como um complemento de outros métodos físico-químicos.


Subject(s)
Norfloxacin/pharmacokinetics , Validation Study , Nephelometry and Turbidimetry , Quality Control , Tablets/pharmacokinetics , Anti-Infective Agents/pharmacokinetics
2.
RBCF, Rev. bras. ciênc. farm. (Impr.) ; 43(2): 231-238, abr.-jun. 2007. ilus, graf, tab
Article in English | LILACS | ID: lil-460183

ABSTRACT

The development and validation of a simple and accurate method based on HPLC with ultraviolet detection for the quantification of norfloxacin (NFX) in human plasma and its application to a bioequivalence study between two norfloxacin formulations is described. NFX and the internal standard (cyprofloxacin) were extracted from plasma using liquid-liquid extraction. Chromatographic separation of norfloxacin, cyprofloxacin and plasma interferents was achieved with a C-18 column and a mobile phase consisting of 20 mM sodium hydrogen phosphate buffer pH 3.0 and acetonitrile (88:12, v/v) and quantitation was done at 280 nm. The method was linear from 25 to 3000 ng mL-1 (r² > 0.997578), and norfloxacin and cyprofloxacin had an average recovery from plasma of 93.9 percent and 91.2 percent respectively. The RSD of inter-day quality control samples at the lower limit of quantification was less than 15 percent. After a single oral dose (400 mg) of norfloxacin administered to healthy human volunteers using a randomized 2x2 crossover design, pharmacokinetic parameters (AUC0-t, AUC0-00, Cmax, t1/2) were derived from the plasma concentration curves for both formulations. Pharmacokinetic analysis of the data showed that the two formulations were bioequivalent, while no adverse reactions to the drug were observed.


O desenvolvimento e validação de um método simples e preciso por CLAE-UV para quantificação de norfloxacino (NFX) em plasma humano e a sua aplicação a um estudo de bioequivalência entre duas formulações são descritos. NFX e o padrão interno (ciprofloxacino, PI) foram extraídos do plasma através de extração líquido-líquido. A separação cromatográfica do NFX, do PI e dos interferentes do plasma foi realizada com uma coluna C-18 e fase móvel composta de tampão fosfato de sódio 20 mM pH 3,0 e acetonitrila (88/12, v/v) e quantificado em 280 nm. A resposta do detector aos analitos mostrou-se linear entre 25 a 3000 ng mL-1 (r² > 0,997578) e a recuperação média de NFX e PI foi de 93,9 por cento e 91,2 por cento respectivamente. O desvio padrão relativo de amostras analisadas ao nível do limite inferior de quantificação foi menor que 15 por cento. Foi administrada uma dose de NFX (400 mg) por via oral a voluntários humanos em um estudo aberto, aleatório e cruzado 2x2 entre duas formulações. Os parâmetros farmacocinéticos (AUC0-t, AUC0-00, Cmáx, T1/2) foram observados a partir da curva de concentração versus tempo. A análise farmacocinética mostrou que as duas formulações são bioequivalentes entre si. Nenhum efeito adverso foi observado.


Subject(s)
Norfloxacin/pharmacokinetics , Plasma/metabolism , Chromatography, Liquid/methods , Therapeutic Equivalency
3.
Medical Journal of Cairo University [The]. 1995; 63 (3): 553-65
in English | IMEMR | ID: emr-38358

ABSTRACT

Twenty five normal male guinea pigs were used to evaluate the effects of norfloxacin, a new antibiotic member of the quinolone group, on the Kidney by means of histological and histochemical techniques. Animals were classified into 5 groups. The first one received no treatment and considered as control group. The second and third groups received the therapeutic dose of the drug orally for one and two weeks respectively. The fourth group received triple the therapeutic dose of the drug for 2 weeks. Double the therapeutic dose was given to the fifth group for 2 weeks, then received no treatment for another 2 weeks, withdrawal group. The Kidneys of animals of the third and fourth groups showed congestion of the interlobular vessels, cloudy swelling of the convoluted tubules with hyaline and granular casts in the lumena of distal and collecting tubules. Decrease of PAS positive materials specially in the brush broders of the tubules, while increase of sudanophilia and acid phosphatase activity in proximal and distal convoluted tubules were noticed. Alkaline phosphatase and G6Pase enzymes were decreased in the convoluted tubules. Non-specific esterase enzyme increased in the proximal convoluted tubules. These changes were more pronounced in the fourth group. The animals of withdrawal group showed normalization of the histological and histochemical picture of the kidney as compared with the control. These results lead to the suggestion that, although the adverse reactions of norfloxacin are reversible, this drug has the risk of occurrence of nephritis specially with increasing the dose and prolongation of the period of treatment


Subject(s)
Animals , Male , Kidney/anatomy & histology , Kidney/drug effects , Alkaline Phosphatase/blood , Norfloxacin/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL